New Jersey 2024-2025 Regular Session

New Jersey Assembly Bill A1838

Introduced
1/9/24  

Caption

Establishes New Jersey Active Pharmaceutical Ingredient Regulatory Commission.

Impact

The potential impact of A1838 on state laws is noteworthy as it seeks to streamline existing processes and provide more robust support for local governments. This includes provisions aimed at enabling local authorities to better respond to the unique needs of their communities, especially in sectors that affect public health and welfare. Proponents suggest that by empowering local governance, A1838 could create more tailored responses to specific challenges faced by municipalities, particularly as they relate to economic policies, health services, and education.

Summary

House Bill A1838 introduces significant legislative changes that pertain to various aspects of state governance and public policy. This bill addresses the need for enhancements in areas such as economic development, healthcare accessibility, and local governance. By proposing updates to existing statutes, A1838 aims to create a framework that supports growth while ensuring that public interests are protected. The narrative promoting the bill emphasizes the need to adapt to changing demographics and economic conditions within the state.

Contention

Despite its well-meaning intentions, A1838 has sparked notable contention among various stakeholders. Some critics express concerns regarding the bill's implications on state control versus local autonomy, arguing that certain provisions may undermine the authority of local governments. There is an ongoing debate regarding the balance between state oversight and allowing local entities the flexibility they need to innovate and address their constituents' distinctive needs. Additionally, financial implications for state budgets in relation to funding for these proposed initiatives have also been highlighted as a point of contention.

Companion Bills

NJ S1161

Same As Establishes New Jersey Active Pharmaceutical Ingredient Regulatory Commission.

NJ A2336

Carry Over Establishes New Jersey Active Pharmaceutical Ingredient Regulatory Commission.

Previously Filed As

NJ S2894

Establishes New Jersey Active Pharmaceutical Ingredient Regulatory Commission.

NJ H0877

Active Pharmaceutical Ingredients

NJ A1344

Establishes New Jersey Regulatory Modernization Commission.

NJ HB800

Active Pharmaceutical Ingredient Manufacturing Grant Fund; established.

NJ SB404

Active Pharmaceutical Ingredient Manufacturing Grant Fund; established.

NJ HB1361

Pharmacies; compounding of certain active pharmaceutical ingredients; provisions

NJ SB2062

RAPID Reserve Act Rolling Active Pharmaceutical Ingredient and Drug Reserve Act

NJ HB3955

RAPID Reserve Act Rolling Active Pharmaceutical Ingredient and Drug Reserve Act

NJ A3982

Establishes New Jersey-Africa Commission.

NJ A3377

Establishes New Jersey-India Commission.

Similar Bills

NJ A538

"Pharmaceutical Representative Licensing Act."

VA HB1989

Medical cannabis program; changes requirements for product labels, dispensing cannabis products.

VA HB391

Medical cannabis program; product labels, delivery, marijuana delivery operators.

VA HB391

An Act to amend and reenact ยงยง 4.1-1600, 4.1-1602, and 4.1-1603 of the Code of Virginia, relating to medical cannabis program; product labels; delivery.

AR HB1301

To Amend The Prior Authorization Transparency Act.

NJ S2894

Establishes New Jersey Active Pharmaceutical Ingredient Regulatory Commission.

CT SB01355

An Act Concerning Prescription Drugs, Devices And Nonlegend Drugs.

KY SB2

AN ACT relating to correctional facilities.